AUSTRALIA'S MEDICINES REGULATOR ADDS PEPTIDES TO PRIORITY SUBSTANCES LIST

Australia's medicines regulator has announced that peptides will be added to a list of priority substances subject to increased scrutiny. Peptides join melatonin, cannabis, and weight loss medications as areas identified for regulatory focus. The move expands enforcement activity across substances available outside official medical channels. The Australian government has also committed $100 million to arthritis research as part of a separate Labour spending announcement.

According to the regulator, the decision to prioritise peptides reflects concerns about their availability and use outside regulated medical frameworks. Melatonin, cannabis, and weight loss medications have already been identified as priority areas. Peptides are compounds used in various medical and performance-enhancement contexts, and the regulator has indicated that their unregulated distribution has drawn attention. The inclusion of peptides alongside these other substances suggests the enforcement activity forms part of a broader regulatory strategy across multiple substance categories.

The $100 million arthritis research commitment represents a significant allocation of public funding towards a condition affecting large numbers of Australians. Labour's decision to announce both measures together places health regulation and medical research funding on the same policy agenda. The peptide priority designation and the research investment address different aspects of healthcare: one targets substances distributed outside regulated channels, whilst the other directs funds into disease management. Both announcements represent confirmed government positions.